Capital International Investors Karuna Therapeutics, Inc. Transaction History

Capital International Investors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$161.01 - $317.85 $38.1 Million - $75.2 Million	236,491 Added 5.93%	4,227,102 $1.34 Billion
Q3 2023 Nov 13, 2023	SELL	$164.66 - $218.08 $319,111 - $422,639	-1,938 Reduced 0.05%	3,990,611 $675 Million
Q2 2023 Aug 11, 2023	BUY	$176.32 - $240.22 $106 Million - $145 Million	602,942 Added 17.79%	3,992,549 $866 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $273 Million - $346 Million	1,694,028 Added 99.91%	3,389,607 $616 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $82.3 Million - $184 Million	664,845 Added 64.5%	1,695,579 $381 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $87.2 Million - $133 Million	927,859 Added 901.93%	1,030,734 $130 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $2.4 Million - $3.21 Million	24,275 Added 30.88%	102,875 $13 Million
Q2 2021 Aug 16, 2021	SELL	$107.45 - $135.95 $31.8 Million - $40.2 Million	-295,600 Reduced 79.0%	78,600 $8.96 Million
Q4 2020 Feb 12, 2021	SELL	$75.23 - $109.23 $6.87 Million - $9.97 Million	-91,300 Reduced 19.61%	374,200 $38 Million
Q3 2020 Nov 13, 2020	SELL	$71.31 - $109.74 $648,921 - $998,634	-9,100 Reduced 1.92%	465,500 $36 Million
Q1 2020 May 15, 2020	BUY	$60.41 - $115.92 $28.7 Million - $55 Million	474,600 New	474,600 $34.2 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.